For help on how to get the results you want, see our search tips.
2 results
Medicine
Referrals Remove Referrals filter
Referral PRAC recommendation
Revocation Remove Revocation filter
Risk minimisation measures Remove Risk minimisation measures filter
Referral status
CMDh final position Remove CMDh final position filter
European Commission final decision Remove European Commission final decision filter
Referral authorisation model
Nationally authorised product(s) Remove Nationally authorised product(s) filter
Centrally authorised product(s) Remove Centrally authorised product(s) filter
Medicine type
Conditional approval Remove Conditional approval filter
Additional monitoring Remove Additional monitoring filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020